UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~June~~August 3014, 2025

Emmaus Life Sciences, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-35527		87-0419387
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

21250 Hawthorne Boulevard, Suite 800, Torrance, CA		90503
(Address of principal executive offices)		(Zip Code)

Registrant’s telephone number, including area code (310) 214-0065

(Former name or former address, if changed, since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol		Name of each exchange on which registered
None

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

~~ITEM~~Item 52.02 ~~Departure~~Results of ~~Directors~~Operation orand ~~Certain~~Financial ~~Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers~~Condition.

~~Effective~~On ~~June~~August 3014, 2025, ~~Mr. Yasushi Nagasaki resigned as Chief Financial Officer of~~ Emmaus Life Sciences, Inc. (“we,” “us,” “our,” “Emmaus” or the “company”) issued a press release announcing our results of operations and ~~indicated~~financial ~~his~~condition ~~plan~~as toof ~~transition~~and for the three months ended June 30, 2025, a copy of which is included as Exhibit 99.1 to ~~full~~this ~~retirement~~Current Report and incorporated herein by reference.

~~Effective~~The information ~~July~~included 1,in ~~2025,~~this MsItem 2.02 ~~Hiroko~~and ~~Huynh~~in ~~was~~Exhibit ~~promoted to~~99.1 ~~serve~~shall asnot ~~our~~be ~~Chief~~deemed ~~Accounting~~“filed” ~~Officer.~~for ~~Ms.~~purposes ~~Huynh~~of ~~has~~Section ~~served~~18 asof ~~Controller~~the ofSecurities Exchange ~~Emmaus~~Act ~~since~~of ~~January~~1934 ~~2020,~~(the ~~and~~“Exchange ~~served~~Act”) asor ~~Senior~~otherwise ~~Manager in~~subject to the ~~finance~~liabilities ~~and~~of ~~accounting~~that ~~department~~section, ~~from~~nor ~~October~~shall ~~2018~~it tobe ~~January~~deemed incorporated ~~2020.~~by ~~Prior~~reference toin ~~joining~~any ~~Emmaus,~~filing ~~she~~under ~~spent~~the ~~eight~~Securities ~~years~~Act asof an1933 ~~accountant with~~or ~~Deloitte~~the &Exchange ~~Touche LLP~~Act, ~~one~~except ofas ~~the~~expressly ~~nation’s~~set ~~“big~~forth ~~four”~~by ~~public~~specific reference ~~accounting~~in ~~firms~~such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

See the accompanying Index to Exhibits, which is incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: July 1, 2025	Emmaus Life Sciences, Inc.
Date: August 14, 2025	Emmaus Life Sciences, Inc.
	By:	/s/ WILLIS LEE
		Willis Lee
		Name:	Willis Lee
		Chairman and Chief Executive Officer
		Title:	Chairman and Chief Executive Officer

INDEX TO EXHIBITS

Exhibit Number		Description
99.1		August 14, 2025 press release
104		Cover Page Interactive Date File (embedded within Inline XBRL document)

Filing Compare · Emmaus Life Sciences, Inc.